Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 94

1.

Determination of estradiol and progesterone content in capsules and creams from compounding pharmacies.

Stanczyk FZ, Niu C, Azen C, Mirkin S, Amadio JM.

Menopause. 2019 Sep;26(9):966-971. doi: 10.1097/GME.0000000000001356.

2.

Early onset of action with a 17β-estradiol, softgel, vaginal insert for treating vulvar and vaginal atrophy and moderate to severe dyspareunia.

Constantine G, Millheiser LS, Kaunitz AM, Parish SJ, Graham S, Bernick B, Mirkin S.

Menopause. 2019 Aug 19. doi: 10.1097/GME.0000000000001394. [Epub ahead of print]

PMID:
31433355
3.

A combined, bioidentical, oral, 17β-estradiol and progesterone capsule for the treatment of moderate to severe vasomotor symptoms due to menopause.

Archer DF, Bernick BA, Mirkin S.

Expert Rev Clin Pharmacol. 2019 Aug;12(8):729-739. doi: 10.1080/17512433.2019.1637731. Epub 2019 Jul 22. Review.

PMID:
31282768
4.

The MATE survey: men's perceptions and attitudes towards menopause and their role in partners' menopausal transition.

Parish SJ, Faubion SS, Weinberg M, Bernick B, Mirkin S.

Menopause. 2019 Oct;26(10):1110-1116. doi: 10.1097/GME.0000000000001373.

PMID:
31188286
5.

Determination of estradiol and progesterone content in capsules and creams from compounding pharmacies.

Stanczyk FZ, Niu C, Azen C, Mirkin S, Amadio JM.

Menopause. 2019 Jun 3. doi: 10.1097/GME.0000000000001356. [Epub ahead of print]

PMID:
31166307
6.

Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review.

Constantine GD, Graham S, Lapane K, Ohleth K, Bernick B, Liu J, Mirkin S.

Menopause. 2019 Jul;26(7):800-807. doi: 10.1097/GME.0000000000001315.

7.

Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules).

Lobo RA, Liu J, Stanczyk FZ, Constantine GD, Pickar JH, Shadiack AM, Bernick B, Mirkin S.

Menopause. 2019 Jul;26(7):720-727. doi: 10.1097/GME.0000000000001306.

8.

Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone.

Mirkin S, Graham S, Revicki DA, Bender RH, Bernick B, Constantine GD.

Menopause. 2019 Jan 9;26(6):637-642. doi: 10.1097/GME.0000000000001294.

9.

Improvement in sleep outcomes with a 17β-estradiol-progesterone oral capsule (TX-001HR) for postmenopausal women.

Kagan R, Constantine G, Kaunitz AM, Bernick B, Mirkin S.

Menopause. 2018 Dec 21;26(6):622-628. doi: 10.1097/GME.0000000000001278.

10.

Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.

Constantine GD, Revicki DA, Kagan R, Simon JA, Graham S, Bernick B, Mirkin S.

Menopause. 2019 May;26(5):513-519. doi: 10.1097/GME.0000000000001261.

11.

Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.

Simon JA, Kaunitz AM, Kroll R, Graham S, Bernick B, Mirkin S.

Menopause. 2019 May;26(5):506-512. doi: 10.1097/GME.0000000000001271.

12.

A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause.

Biehl C, Plotsker O, Mirkin S.

Menopause. 2019 Apr;26(4):431-453. doi: 10.1097/GME.0000000000001221.

PMID:
30363010
13.

Estradiol vaginal inserts (4 µg and 10 µg) for treating moderate to severe vulvar and vaginal atrophy: a review of phase 3 safety, efficacy and pharmacokinetic data.

Constantine GD, Simon JA, Pickar JH, Archer DF, Bernick B, Graham S, Mirkin S.

Curr Med Res Opin. 2018 Dec;34(12):2131-2136. doi: 10.1080/03007995.2018.1527578. Epub 2018 Sep 28.

PMID:
30238814
14.

WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history.

Kingsberg SA, Larkin L, Krychman M, Parish SJ, Bernick B, Mirkin S.

Menopause. 2019 Feb;26(2):124-131. doi: 10.1097/GME.0000000000001194.

15.

To the Editor.

Archer DF, Pickar JH, Constantine GD, Shadiack AM, Bernick B, Mirkin S.

Menopause. 2018 Aug;25(8):952-953. doi: 10.1097/GME.0000000000001146. No abstract available.

PMID:
29944639
16.

A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.

Lobo RA, Archer DF, Kagan R, Kaunitz AM, Constantine GD, Pickar JH, Graham S, Bernick B, Mirkin S.

Obstet Gynecol. 2018 Jul;132(1):161-170. doi: 10.1097/AOG.0000000000002645. Erratum in: Obstet Gynecol. 2018 Sep;132(3):786.

PMID:
29889748
17.

Vaginal pH: a simple assessment highly correlated with vaginal morphology and symptoms in postmenopausal women.

Tucker KM, Godha K, Mirkin S, Archer DF.

Menopause. 2018 Jul;25(7):762-766. doi: 10.1097/GME.0000000000001081.

PMID:
29509598
18.

Human vaginal pH and microbiota: an update.

Godha K, Tucker KM, Biehl C, Archer DF, Mirkin S.

Gynecol Endocrinol. 2018 Jun;34(6):451-455. doi: 10.1080/09513590.2017.1407753. Epub 2017 Dec 22. Review.

PMID:
29271266
19.

In Reply.

Archer DF, Constantine GD, Simon J, Kushner H, Mayer P, Bernick B, Graham S, Mirkin S.

Menopause. 2017 Aug;24(8):988-989. doi: 10.1097/GME.0000000000000940. No abstract available.

PMID:
28719419
20.

Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial.

Simon JA, Archer DF, Kagan R, Bernick B, Graham S, Constantine GD, Mirkin S.

Menopause. 2017 Sep;24(9):1003-1010. doi: 10.1097/GME.0000000000000880.

Supplemental Content

Loading ...
Support Center